Check-Cap Ltd. (NASDAQ:CHEK) Sees Large Drop in Short Interest

Check-Cap Ltd. (NASDAQ:CHEK – Get Rating) was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 25,600 shares, a decrease of 6.6% from the January 31st total of 27,400 shares. Based on an average trading volume of 74,600 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.4% of the company’s shares are short sold.

Hedge Funds Weigh In On Check-Cap

A hedge fund recently raised its stake in Check-Cap stock. Virtu Financial LLC grew its holdings in shares of Check-Cap Ltd. (NASDAQ:CHEK – Get Rating) by 363.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 224,696 shares of the medical research company’s stock after acquiring an additional 176,207 shares during the quarter. Virtu Financial LLC owned 0.23% of Check-Cap worth $69,000 at the end of the most recent quarter. Institutional investors own 17.59% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Check-Cap in a research report on Tuesday. They issued a “sell” rating for the company.

Check-Cap Stock Down 0.9 %

Shares of NASDAQ:CHEK opened at $3.29 on Wednesday. The firm has a market capitalization of $15.86 million and a price-to-earnings ratio of -1.02. Check-Cap has a twelve month low of $1.88 and a twelve month high of $9.20. The stock’s 50 day moving average is $3.21 and its 200-day moving average is $4.35.

About Check-Cap

(Get Rating)

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer.